Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen EPO Patent Win Over Roche Could Derail Mircera Launch

This article was originally published in The Pink Sheet Daily

Executive Summary

Boston jury finds Roche’s Mircera infringes Amgen’s erythropoietin patents and that all five Amgen patents are valid.

You may also be interested in...



Roche Appeals Mircera Injunction

Company seeks to overturn move barring anemia launch in the U.S.

Roche Appeals Mircera Injunction

Company seeks to overturn move barring anemia launch in the U.S.

Roche Agrees To Court Conditions For Mircera Launch

Roche says it will price Mircera at or below Epogen and pay Amgen a 22.5 percent royalty; Amgen presses for a permanent injunction against drug’s launch.

Related Content

Topics

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel